“Unconventional CD147‐dependent platelet activation elicited by SARS‐CoV‐2 in COVID‐19”: Reply

Repurposing niclosamide as a novel anti-SARS-Cov-2 drug by restricting entry protein CD147

“…Also, by analyzing patient platelet indices and COVID-19 transcriptomic signatures, a recent study reported that megakaryocytes actively internalize SARS-CoV-2 through CD147, and that patient platelets had a unique proin ammatory transcriptome and were hyperreactive 21 . Alongside this nding, another study revealed CD147-dependent platelet activation upon SARS-CoV-2 interaction 22 , which further pinpointed the functional role of CD147 in SARS-CoV-2 infection. Besides, CD147 receptor mediated signaling has been shown to participate in the disruption of cardiac pericytes by SARS-CoV-2 spike protein 23 .…”

“…An ongoing debate on whether CD147 serves as a potential entry for SARS-CoV-2 had portrayed CD147 an ambiguous protein to de ne 11,60 , as both labs presenting their data from different perspectives. However, a recent clinical trial targeting CD147 showed its promise to speed up the recovery of COVID-19 patients 25 , and different groups had revealed the potential CD147 interaction with SARS-CoV-2 on megakaryocytes, platelets, human CD147 knock-in NSG mice model, and iPSC-derived kidney podocytes model 18,19,21,22 . Combined with the fact that CD147 had been shown to participate in the brosis progression [61][62][63] , especially the HG form 58 , collectively, these results strongly argue CD147 a promising target for limiting COVID-19 disease and post COVID-19 conditions.…”